Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.59 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.59 |
| ▸ | TYMP | P19971 | 2/20 | 0.59 |
| ▸ | NT5E | P21589 | 14/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20350582 | 1.00 | PNP (0.59) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL7608943 | 0.91 | TYMP (0.59) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL7607071 | 0.91 | TYMP (0.59) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL7871248 | 0.88 | TYMP (0.63) | TYMPNT5EADORA1 | |
| SCHEMBL1774839 | 0.88 | TYMP (0.63) | TYMPNT5EADORA1 | |
| SCHEMBL29529385 | 0.88 | TYMP (0.63) | TYMPNT5EADORA1 | |
| SCHEMBL1774838 | 0.88 | TYMP (0.63) | TYMPNT5EADORA1 | |
| SCHEMBL29574745 | 0.88 | TYMP (0.63) | TYMPNT5EADORA1 | |
| SCHEMBL22216349 | 0.87 | PNP (0.44) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL24835606 | 0.87 | NT5E (0.63) | TYMPNT5EADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11034715-B2 | Ectonucleotidase inhibitors and methods of use thereof | CALITHERA BIOSCIENCES, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-20200223882-A1 | Ectonucleotidase Inhibitors and Methods of Use Thereof | ANTENGENE THERAPEUTICS LIMITED (CN) | 2020-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200223882-A1 | Ectonucleotidase Inhibitors and Methods of Use Thereof | NT5E, ENTPD5, NT5C2 | PNP 31/4885LMNA 2684/4885TP53 2516/4885 |
| US-11034715-B2 | Ectonucleotidase inhibitors and methods of use thereof | NT5E, ENTPD5, NT5C2 | PNP 31/4885LMNA 2684/4885TP53 2516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.